A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)HPV (human Papillomavirus)-Associated CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Biological: BVAC-E6E7 (low level)Biological: BVAC-E6E7 (high level)Biological: BVAC-E6E7 (RP2D)
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT06797986
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
- Conditions
- COVID-19Vaccines
- Interventions
- Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)Biological: AdCLD-CoV19-1 OMI
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 4000
- Registration Number
- NCT05993325
- Locations
- 🇰🇷
Dong-a University Hospital, Busan, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Korea, Republic of
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
- Conditions
- VaccinesCOVID-19
- Interventions
- Other: Placebo (Part B)Biological: AdCLD-CoV19-1 OMI (Part B)Biological: AdCLD-CoV19-1 OMI (Part A)
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT05576623
- Locations
- 🇰🇷
Hallym University Dongtan Sacred Heart Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea ST. Vincent's Hospital, Gyeonggi-do, Korea, Republic of
Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1
- Conditions
- COVID-19Vaccines
- Interventions
- Biological: AdCLD-CoV19-1
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT05520970
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Catholic University Seoul St.Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
- Conditions
- Covid19
- Interventions
- Biological: AdCLD-CoV19-1
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05047692
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Province, Korea, Republic of
🇰🇷The Catholic University of Korea, ST. Vincent's Hospital, Suwon, Province, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, State, Korea, Republic of
Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
- Conditions
- COVID-19
- Interventions
- Biological: AdCLD-CoV19
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04666012
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Province, Korea, Republic of
🇰🇷The Catholic University of Korea, ST. Vincent's Hospital, Suwon, Province, Korea, Republic of
🇰🇷Hallym University Kangnam Sacred Heart Hospital, Seoul, State, Korea, Republic of
Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care
- Conditions
- Stomach Neoplasms
- Interventions
- Biological: BVAC-B
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT03425773
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT02866006
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of